atelozumab
Atezolizumab intravenous 1200 mg fixed dose every 3 weeks
docetaxel
docetaxel at 75 mg/m² every 3 weeks
No crossover to atezolizumab was allowed
mNSCLC - L2 - PDL1 positive
Patients with EGFR mutations or an ALK fusion oncogene were additionally required to have received previous tyrosine kinase inhibitor therapy.
open label
194 academic or community oncology centres in 31 countries
P3/ two sided no interim analysis planned. A splitting between the ITT population [a=3%] and the PDL1 TC1/2/3 or IC1/2/3 population [a=2%]) and reallocation 5% to OS SG TC2/3 and then TC3 was planned. an initial analysis with 850 patients was planned, but an amendement modified the population to 1225 before the analysis
Atezolizumab treatment significantly improve overall survival versus docetaxel in previously treated non-small-cell lung cancer, regardless of PD-L1 expression or histology